Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Volkin

Showing results (151-160 of 175) with videos related to

Pageof 18
Sort By:
Human Vaccines & Immunotherapeutics|August 9, 2013
Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccineVidyashankara Iyer, Lei Hu, Carole E Schanté, et al.
Gut Microbes|January 13, 2021
Investigation of a monoclonal antibody against enterotoxigenic <i>Escherichia coli</i>, expressed as secretory IgA1 and IgA2 in plantsAudrey Y-H Teh, Lisa Cavacini, Yue Hu, et al.
Biologicals : Journal of the International Association of Biological Standardization|October 5, 2010
Comparability assessments of process and product changes made during development of two different monoclonal antibodiesAnthony Lubiniecki, David B Volkin, Marcia Federici, et al.
Journal of Pharmaceutical Sciences|February 19, 2019
Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine AntigensNeal Whitaker, John M Hickey, Kawaljit Kaur, et al.
Journal of Pharmaceutical Sciences|December 3, 2022
Multi-dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part II- Real-time and Accelerated Stability StudiesNitya Sharma, Kaushal Jerajani, Ying Wan, et al.
Journal of Pharmaceutical Sciences|August 23, 2011
Biophysical characterization and conformational stability of Ebola and Marburg virus-like particlesLei Hu, Jared M Trefethen, Yuhong Zeng, et al.
Journal of Pharmaceutical Sciences|June 4, 2004
Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccinesRobert K Evans, De-Min Zhu, Danilo R Casimiro, et al.
Journal of Pharmaceutical Sciences|September 12, 2022
Multi-Dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part I - Screening of Preservative CombinationsKaushal Jerajani, Ying Wan, Ozan S Kumru, et al.
Journal of Pharmaceutical Sciences|December 5, 2020
Mechanism of Thimerosal-Induced Structural Destabilization of a Recombinant Rotavirus P[4] Protein Antigen Formulated as a Multi-Dose VaccineKawaljit Kaur, Jian Xiong, Nishant Sawant, et al.
The Pediatric Infectious Disease Journal|October 11, 2003
Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulationH Fred Clark, Carl J Burke, David B Volkin, et al.
Pageof 18

Showing results (151-160 of 175) with videos related to

Sort By:
Pageof 18
Human Vaccines & Immunotherapeutics|August 9, 2013
Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccineVidyashankara Iyer, Lei Hu, Carole E Schanté, et al.
Gut Microbes|January 13, 2021
Investigation of a monoclonal antibody against enterotoxigenic <i>Escherichia coli</i>, expressed as secretory IgA1 and IgA2 in plantsAudrey Y-H Teh, Lisa Cavacini, Yue Hu, et al.
Biologicals : Journal of the International Association of Biological Standardization|October 5, 2010
Comparability assessments of process and product changes made during development of two different monoclonal antibodiesAnthony Lubiniecki, David B Volkin, Marcia Federici, et al.
Journal of Pharmaceutical Sciences|February 19, 2019
Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine AntigensNeal Whitaker, John M Hickey, Kawaljit Kaur, et al.
Journal of Pharmaceutical Sciences|December 3, 2022
Multi-dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part II- Real-time and Accelerated Stability StudiesNitya Sharma, Kaushal Jerajani, Ying Wan, et al.
Journal of Pharmaceutical Sciences|August 23, 2011
Biophysical characterization and conformational stability of Ebola and Marburg virus-like particlesLei Hu, Jared M Trefethen, Yuhong Zeng, et al.
Journal of Pharmaceutical Sciences|June 4, 2004
Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccinesRobert K Evans, De-Min Zhu, Danilo R Casimiro, et al.
Journal of Pharmaceutical Sciences|September 12, 2022
Multi-Dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part I - Screening of Preservative CombinationsKaushal Jerajani, Ying Wan, Ozan S Kumru, et al.
Journal of Pharmaceutical Sciences|December 5, 2020
Mechanism of Thimerosal-Induced Structural Destabilization of a Recombinant Rotavirus P[4] Protein Antigen Formulated as a Multi-Dose VaccineKawaljit Kaur, Jian Xiong, Nishant Sawant, et al.
The Pediatric Infectious Disease Journal|October 11, 2003
Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulationH Fred Clark, Carl J Burke, David B Volkin, et al.
Pageof 18